KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Leases: 2019-2025

Historic Capital Leases for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $55.7 million.

  • Aurinia Pharmaceuticals' Capital Leases fell 15.51% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 15.51%. This contributed to the annual value of $58.6 million for FY2024, which is 22.42% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Capital Leases stood at $55.7 million for Q3 2025, which was down 6.00% from $59.3 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Capital Leases' 5-year high stood at $79.4 million during Q2 2023, with a 5-year trough of $55.7 million in Q3 2025.
  • In the last 3 years, Aurinia Pharmaceuticals' Capital Leases had a median value of $65.4 million in 2024 and averaged $65.6 million.
  • Data for Aurinia Pharmaceuticals' Capital Leases shows a maximum YoY decreased of 22.42% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Aurinia Pharmaceuticals' Capital Leases stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024, then decreased by 15.51% to $55.7 million in 2025.
  • Its Capital Leases stands at $55.7 million for Q3 2025, versus $59.3 million for Q2 2025 and $56.8 million for Q1 2025.